Nuvation Bio (NYSE:NUVB) Sees Strong Trading Volume on Earnings Beat

Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) saw strong trading volume on Tuesday after the company announced better than expected quarterly earnings. 6,780,232 shares were traded during trading, an increase of 34% from the previous session's volume of 5,075,067 shares.The stock last traded at $4.5760 and had previously closed at $5.17.

The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.01. The company had revenue of $13.12 million for the quarter, compared to analysts' expectations of $7.48 million. Nuvation Bio had a negative net margin of 1,413.43% and a negative return on equity of 46.14%.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NUVB shares. Citizens Jmp lifted their price objective on shares of Nuvation Bio from $6.00 to $8.00 and gave the stock a "market outperform" rating in a research note on Tuesday. Weiss Ratings reissued a "sell (d-)" rating on shares of Nuvation Bio in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Nuvation Bio from a "sell" rating to a "hold" rating in a research report on Sunday, August 17th. Royal Bank Of Canada lifted their target price on shares of Nuvation Bio from $6.00 to $7.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, Citigroup reaffirmed a "market outperform" rating on shares of Nuvation Bio in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Nuvation Bio presently has an average rating of "Moderate Buy" and a consensus price target of $8.43.

Read Our Latest Analysis on Nuvation Bio

Insider Buying and Selling

In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of the business's stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $5.02, for a total value of $502,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 29.93% of the stock is owned by corporate insiders.

Institutional Trading of Nuvation Bio

Several large investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its holdings in shares of Nuvation Bio by 52.4% during the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock worth $6,642,000 after buying an additional 1,298,131 shares during the period. Natixis acquired a new position in Nuvation Bio during the 2nd quarter valued at $1,766,000. Marshall Wace LLP acquired a new position in Nuvation Bio during the 2nd quarter valued at $1,699,000. Geode Capital Management LLC raised its stake in Nuvation Bio by 16.8% during the 2nd quarter. Geode Capital Management LLC now owns 5,994,798 shares of the company's stock valued at $11,691,000 after purchasing an additional 864,194 shares during the last quarter. Finally, AWM Investment Company Inc. acquired a new position in Nuvation Bio during the 1st quarter valued at $1,144,000. 61.67% of the stock is owned by institutional investors.

Nuvation Bio Trading Down 12.0%

The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -7.15 and a beta of 1.48. The company's 50 day moving average is $3.68 and its 200 day moving average is $2.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 9.38 and a current ratio of 9.39.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.

Further Reading

• Five stocks we like better than Nuvation Bio
• Growth Investing: Should You Adopt This Investing Strategy in 2022?
• Intel's SambaNova Play Isn't an Acquisition, It's an Ambush
• How to trade using analyst ratings
• Why Roblox Stock Could Soar 75% After the Q3 Dip
• About the Markup Calculator
• Amazon vs. Apple: Which Mag 7 Is the Better Buy?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Nuvation Bio Right Now?

Before you consider Nuvation Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.

While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here